Summaries of health policy coverage from major news organizations
California Company in Final Clinical Testing Stages for Genotypic Test
Applied BioSystemsGroup of Foster City, Calif., is in the final stages of clinical testing for the ViroSeq HIV-1 Genotyping System, its version of a
genotypic test that will help doctors tailor patients'
antiHIV medication regimens by identifying resistant strains of the virus, the Silicon Valley/San Jose Business Journal reports. The company expects to submit the results to the FDA for approval in the second quarter of this year and hopes to go to market early next year. The tests, which run on the company's gene sequencers that were used in decoding the human genome, seek to "eliminat[e] much of the trial and error associated with AIDS treatment" by sequencing the genetic makeup of HIV, thereby determining what drugs will and will not work in a particular patient. Doctors would use the test every time they adjusted a patient's medications, an average of twice a year. The estimated worldwide market for such tests is about $300 million.
This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.